DOXIL® (doxorubicin HCl liposome injection) infusion considerations
Prior to administration, the appropriate dose of DOXIL® must be diluted in 5% dextrose injection, USP (D5W).
If DOXIL® comes into contact with skin or mucosa, immediately wash thoroughly with soap and water.1
Assess baseline clinical status1,2
- Check and monitor vital signs2
- Complete blood count and liver function should be monitored prior to each dose2
- Assess for signs and symptoms of hand-foot syndrome and stomatitis2
- Have appropriate medications and emergency equipment readily available for immediate use to help treat infusion-related reactions1
- Assess left ventricular cardiac function (eg, MUGA or echocardiogram) prior to initiation of DOXIL®
- Also assess during treatment to detect acute changes, and after treatment to detect delayed cardiotoxicity
Start IV line with D5W1
- Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if a precipitate or foreign matter is present
- DO NOT1
- Use with in-line filters
- Administer as a bolus injection or as an undiluted solution
- Mix with other drugs
- Substitute DOXIL® for doxorubicin HCl injection
- Administer as an undiluted suspension or as an intravenous bolus
Start DOXIL® infusion at 1 mg/min to minimize the risk of infusion reactions1
- If no infusion-related adverse reactions are observed, the rate of infusion can be increased to complete administration of DOXIL® over 1 hour
- Do not rapidly flush the infusion line
DOXIL® is a cytotoxic drug. Follow special handling and disposal procedures.
No formal drug interaction studies have been conducted with DOXIL®.1
Instruct patients to alert you and your team of healthcare professionals if they:
- Develop any symptoms of heart failure (cardiomyopathy)
- Experience discoloration (reddish-orange color) of urine and other body fluids
- Experience a burning or stinging sensation or other evidence indicating perivenous infiltration or extravasation
- Develop a fever or symptoms of infection (myelosuppression)
- Experience tingling or burning, redness, flaking, bothersome swelling, small blisters, or small sores on the palms of their hands or soles of their feet (hand-foot syndrome)
- Develop painful redness, swelling, or sores in the mouth (stomatitis)
- Suspect that they may be pregnant, or may become pregnant during treatment with DOXIL®
- Advise patients not to breastfeed during treatment with DOXIL®
- Advise females and males of reproductive potential to use effective contraception during and for 6 months following treatment with DOXIL®, and that treatment with DOXIL® may cause temporary or permanent infertility
Advise patients about the symptoms of infusion-related reactions and to seek immediate medical attention if they develop any of these symptoms.
DOXIL® (doxorubicin HCl liposome injection) Prescribing Information. Janssen Products, LP, Horsham, PA.
Data on file. Janssen Products, LP, Horsham, PA.